(CercleFinance.com) – Eurobio Scientific and Acobiom, a French company specializing in the identification of biomarkers and the development of molecular diagnostics for precision medicine, announce the signing of an exclusive commercial agreement in France, Germany and the United Kingdom for the distribution of GemciTest®, a predictive diagnostic test for response to pancreatic cancer treatment.
In France, this cancer affected approximately 15,000 patients in 2020, of which nearly 45% would be at the metastatic stage. The diagnosis is usually made by imaging and biological tests on biopsy.
GemciTest®, an in-vitro diagnostic developed by Acobiom, is a predictive PCR test for response to first-line gemcitabine-based chemotherapy. It will make it possible to orient patients towards another more suitable or more effective therapy, to avoid unnecessary side effects or toxicities, and therefore to risk a ‘loss of chance’ for these patients.